RS51885B - PIRIDIN[3,4-b] PIRAZINONI - Google Patents

PIRIDIN[3,4-b] PIRAZINONI

Info

Publication number
RS51885B
RS51885B RS20110363A RSP20110363A RS51885B RS 51885 B RS51885 B RS 51885B RS 20110363 A RS20110363 A RS 20110363A RS P20110363 A RSP20110363 A RS P20110363A RS 51885 B RS51885 B RS 51885B
Authority
RS
Serbia
Prior art keywords
group
substituted
optionally
independently selected
propoxyethyl
Prior art date
Application number
RS20110363A
Other languages
English (en)
Serbian (sr)
Inventor
Christopher Phillips
Robert O. Hughes
Dafydd Rhys Owen
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Eric Jon Jacobsen
Todd Michael Maddux
Brent Virgil Mischke
John Majo Molyneaux
Joseph Blair Moon
Donald Joseph Rogier Jr.
Michael Brent Tollefson
John Keith Walker
David Graham Brown
Michael John Palmer
Andrew Simon Bell
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of RS51885B publication Critical patent/RS51885B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
RS20110363A 2006-04-21 2007-04-10 PIRIDIN[3,4-b] PIRAZINONI RS51885B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
RS51885B true RS51885B (sr) 2012-02-29

Family

ID=38431249

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP-2008/0484A RS20080484A (sr) 2006-04-21 2007-04-10 PIRIDIN[3,4-b] PIRAZINONI
RS20110363A RS51885B (sr) 2006-04-21 2007-04-10 PIRIDIN[3,4-b] PIRAZINONI

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RSP-2008/0484A RS20080484A (sr) 2006-04-21 2007-04-10 PIRIDIN[3,4-b] PIRAZINONI

Country Status (41)

Country Link
US (1) US7902195B2 (enExample)
EP (1) EP2013208B1 (enExample)
JP (1) JP4436892B2 (enExample)
KR (1) KR101061328B1 (enExample)
CN (1) CN101454320B (enExample)
AP (1) AP2408A (enExample)
AR (1) AR060525A1 (enExample)
AT (1) ATE513831T1 (enExample)
AU (1) AU2007242555B2 (enExample)
BR (1) BRPI0710658A2 (enExample)
CA (1) CA2649775C (enExample)
CR (1) CR10327A (enExample)
CU (1) CU23777B7 (enExample)
CY (1) CY1111739T1 (enExample)
DK (1) DK2013208T3 (enExample)
DO (1) DOP2007000080A (enExample)
EA (1) EA014919B1 (enExample)
EC (1) ECSP088803A (enExample)
ES (1) ES2366239T3 (enExample)
GT (1) GT200700035A (enExample)
HR (1) HRP20110539T1 (enExample)
IL (1) IL194591A (enExample)
MA (1) MA30352B1 (enExample)
ME (1) MEP23808A (enExample)
MX (1) MX2008012456A (enExample)
MY (1) MY148583A (enExample)
NL (1) NL2000583C2 (enExample)
NO (1) NO20084129L (enExample)
NZ (1) NZ571540A (enExample)
PA (1) PA8724201A1 (enExample)
PE (1) PE20080192A1 (enExample)
PL (1) PL2013208T3 (enExample)
RS (2) RS20080484A (enExample)
SI (1) SI2013208T1 (enExample)
SV (1) SV2008003074A (enExample)
TN (1) TNSN08408A1 (enExample)
TW (1) TWI337609B (enExample)
UA (1) UA92637C2 (enExample)
UY (1) UY30291A1 (enExample)
WO (1) WO2007122466A1 (enExample)
ZA (1) ZA200808283B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649775C (en) 2006-04-21 2011-05-31 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
EP2952193A1 (en) * 2006-12-12 2015-12-09 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
MX2010009577A (es) * 2008-03-05 2010-09-24 Merck Patent Gmbh Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
WO2010041711A1 (ja) * 2008-10-09 2010-04-15 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
CN106117213B (zh) * 2009-10-26 2022-03-18 西格诺药品有限公司 杂芳基化合物及其合成和纯化方法
US20120269898A1 (en) 2010-10-15 2012-10-25 Luiz Belardinelli Compositions and methods of treating pulmonary hypertension
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
EP3052495B1 (en) 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
WO2015150957A1 (en) 2014-04-01 2015-10-08 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
PE20170327A1 (es) 2014-04-10 2017-04-21 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
UA125334C2 (uk) 2015-06-17 2022-02-23 Пфайзер Інк. Трициклічні сполуки та їх застосування як інгібіторів фосфодіестерази
EP3353183A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
AU2017223132B2 (en) 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
CN109641898B (zh) 2016-07-01 2022-04-08 辉瑞公司 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
IL271290B2 (en) 2017-06-22 2023-11-01 Pfizer Dihydro-pyrrolo-pyridine derivatives
WO2019005980A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
PT3768669T (pt) 2018-03-23 2023-04-24 Pfizer Derivados de piperazina azaspiro
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025160132A1 (en) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Gpr6 inverse agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
JP2550456B2 (ja) * 1990-11-06 1996-11-06 山之内製薬株式会社 縮合ピラジン誘導体
TW274550B (enExample) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
AU2002233706C1 (en) * 2001-02-26 2005-12-22 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
JP2007504283A (ja) * 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
EP1641423B1 (en) * 2003-06-26 2010-03-17 Merck Sharp & Dohme Corp. Benzodiazepine cgrp receptor antagonists
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
WO2006074223A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
KR20080052611A (ko) * 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2649775C (en) 2006-04-21 2011-05-31 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones

Also Published As

Publication number Publication date
ES2366239T3 (es) 2011-10-18
EP2013208A1 (en) 2009-01-14
AU2007242555A1 (en) 2007-11-01
CY1111739T1 (el) 2015-10-07
NO20084129L (no) 2008-10-29
JP2009534368A (ja) 2009-09-24
TWI337609B (en) 2011-02-21
ECSP088803A (es) 2008-11-27
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
AP2008004640A0 (en) 2008-10-31
NL2000583A1 (nl) 2007-10-23
CU20080194A7 (es) 2011-03-21
MY148583A (en) 2013-04-30
US20070249615A1 (en) 2007-10-25
HK1133875A1 (en) 2010-04-09
RS20080484A (sr) 2009-07-15
CR10327A (es) 2008-10-21
EA014919B1 (ru) 2011-04-29
AU2007242555B2 (en) 2010-12-16
MEP23808A (en) 2010-06-10
DOP2007000080A (es) 2007-11-15
BRPI0710658A2 (pt) 2011-08-16
ZA200808283B (en) 2009-11-25
HRP20110539T1 (hr) 2011-08-31
EA200801998A1 (ru) 2009-04-28
GT200700035A (es) 2008-02-05
IL194591A (en) 2012-07-31
ATE513831T1 (de) 2011-07-15
WO2007122466A1 (en) 2007-11-01
CA2649775C (en) 2011-05-31
SV2008003074A (es) 2010-01-12
DK2013208T3 (da) 2011-08-15
JP4436892B2 (ja) 2010-03-24
PE20080192A1 (es) 2008-03-01
MX2008012456A (es) 2008-10-10
KR20080110930A (ko) 2008-12-19
NZ571540A (en) 2010-10-29
PL2013208T3 (pl) 2011-10-31
UY30291A1 (es) 2007-11-30
MA30352B1 (fr) 2009-04-01
SI2013208T1 (sl) 2011-09-30
EP2013208B1 (en) 2011-06-22
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
TNSN08408A1 (fr) 2010-04-14
US7902195B2 (en) 2011-03-08
CU23777B7 (es) 2012-02-15
KR101061328B1 (ko) 2011-08-31
AR060525A1 (es) 2008-06-25
CA2649775A1 (en) 2007-11-01
PA8724201A1 (es) 2009-08-26
CN101454320A (zh) 2009-06-10
TW200808794A (en) 2008-02-16

Similar Documents

Publication Publication Date Title
RS51885B (sr) PIRIDIN[3,4-b] PIRAZINONI
JP5959541B2 (ja) Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2006126081A2 (en) Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2006126082A2 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
JP2023511084A (ja) Ｐｇｄｈ阻害剤、およびその作製と使用の方法
AU2019228568B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
ES2997267T3 (en) Azole-fused pyridazin-3(2h)-one derivatives
TW202122382A (zh) 乙內醯脲衍生物
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
HRP20050926A2 (en) Beta-carbolines useful for treating inflammatory disease
RS20060584A (sr) Beta-karbolini koji su korisni za lečenje inflamatorne bolesti
US10351558B2 (en) Factor IXa inhibitors
WO2007020521A1 (en) Pyridoyrazinones as pde-5 inhibitors
JP2008517994A (ja) 新規医薬品
HK1133875B (en) Pyridine[3,4-b]pyrazinones
WO2025233837A1 (en) 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
WO2025102016A1 (en) Novel molecules as inhibitors of dna damage repair pathway